+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer



RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer



Journal of Clinical Oncology 22(10): 1878-1885



RRM1 has important functions in the determination of the malignant phenotype. It controls cell proliferation through deoxynucleotide production and metastatic propensity through PTEN induction. It is located in a region of loss of heterozygosity in non-small-cell lung cancer (NSCLC), which is a predictor of poor survival. We hypothesized that RRM1 expression would be a significant predictor of outcome in NSCLC. A retrospective data set of 49 patients and a prospective data set of 77 patients with resectable NSCLC were studied. RNA was extracted from tumor and normal lung tissue, and expression of the genes RRM1, PTEN, and RRM2 was determined by real-time quantitative polymerase chain reaction. RRM1 expression was significantly correlated with PTEN and RRM2 expression in tumor tissue. RRM1 and PTEN expression in tumor tissue was highly predictive of overall (P =.011 and.018, respectively) and disease-free survival (P =.002 and.026, respectively). Patients with high levels of expression lived longer and had disease recurrence later than patients with low levels of RRM1 and PTEN. In a multivariate analysis, high RRM1 expression was predictive of long survival independent of tumor stage, performance status, and weight loss. RRM1 is a biologically and clinically important determinant of malignant behavior in NSCLC. Knowing the level of expression of this gene adds significant information to management decisions independent of the currently used outcome predictors of tumor stage, performance status, and weight loss. Future clinical trials should stratify patients based on expression of this gene to avoid unwanted biases.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 050097358

Download citation: RISBibTeXText

PMID: 15143080

DOI: 10.1200/jco.2004.12.002


Related references

The prognostic value of ERCC1 and RRM1 gene expression in completely resected non-small cell lung cancer: tumor recurrence and overall survival. Cancer Management and Research 5: 327-336, 2013

Prognostic value of preoperative metabolic tumor volumes on PET-CT in predicting disease-free survival of patients with stage I non-small cell lung cancer. Anticancer Research 32(11): 5087-5091, 2012

Prognostic value of ERCC1, RRM1, and TS proteins in patients with resected non-small cell lung cancer. Cancer ChemoTherapy and Pharmacology 75(4): 861-867, 2015

Genetic alterations of driver genes as independent prognostic factors for disease-free survival in patients with resected non-small cell lung cancer. Lung Cancer 128: 152-157, 2019

Prognostic significance of ERCC1, RRM1 and BRCA1 in surgically-treated patients with non-small cell lung cancer. Anticancer Research 32(11): 5003-5010, 2012

Prognostic factors for disease-free survival in pT2N0 non-small cell lung cancer. Asian Cardiovascular and Thoracic Annals 14(2): 139-144, 2006

Prognostic significance of BRCA1, ERCC1, RRM1, and RRM2 in patients with advanced non-small cell lung cancer receiving chemotherapy. Tumour Biology 35(12): 12679-12688, 2014

Prognostic significance of the mRNA expression of ERCC1 , RRM1 , TUBB3 and TYMS genes in patients with non-small cell lung cancer. Experimental and Therapeutic Medicine 10(3): 937-941, 2015

Loss of 4q21.23-22.1 is a prognostic marker for disease free and overall survival in non-small cell lung cancer. Plos one 9(12): E113315, 2014

A robust six-gene prognostic signature for prediction of both disease-free and overall survival in non-small cell lung cancer. Journal of Translational Medicine 17(1): 152, 2019

Preoperative lymphocyte count is a favorable prognostic factor of disease-free survival in non-small-cell lung cancer. Medical Oncology 30(1): 352, 2013

Predictors of survival and disease-free survival in patients with resected N1 non-small cell lung cancer. Annals of Thoracic Surgery 84(1): 182-8; Discussion 189-90, 2007

Differential effect of polymorphisms of CMPK1 and RRM1 on survival in advanced non-small cell lung cancer patients treated with gemcitabine or taxane/cisplatinum. Journal of Thoracic Oncology 6(8): 1320-1329, 2011

Interleukin polymorphisms associated with overall survival, disease-free survival, and recurrence in non-small cell lung cancer patients. Molecular Carcinogenesis 54(Suppl. 1): E172-E184, 2015

The Prognostic Value of the Tumor Shrinkage Rate for Progression-Free Survival in Patients with Non-Small Cell Lung Cancer Receiving Gefitinib. Tuberculosis and Respiratory Diseases 78(4): 315-320, 2015